Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis

被引:5
作者
Vuorinen, Anna [1 ,2 ,3 ]
Engeli, Roger T. [3 ]
Leugger, Susanne [3 ]
Kreutz, Christoph R. [4 ,5 ]
Schuster, Daniela [1 ,2 ]
Odermatt, Alex [3 ]
Matuszczak, Barbara [1 ,2 ]
机构
[1] Univ Innsbruck, Inst Pharm Pharmaceut Chem, Innrain 80-82, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, CMBI, Innrain 80-82, A-6020 Innsbruck, Austria
[3] Univ Basel, Div Mol & Syst Toxicol, Dept Pharmaceut Sci, Klingelbergstr 50, CH-4056 Basel, Switzerland
[4] Univ Innsbruck, Inst Organ Chem, Innrain 80-82, A-6020 Innsbruck, Austria
[5] Univ Innsbruck, Ctr Mol Biosci CMBI, Innrain 80-82, A-6020 Innsbruck, Austria
基金
瑞士国家科学基金会;
关键词
17; beta-HSD2; Inhibitor; Osteoporosis; Virtual screening; Estrogen; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; DISCOVERY; EXPRESSION; LOCALIZATION; HEPATOCYTES; MANAGEMENT; TOXICITY; PLACENTA;
D O I
10.1016/j.bmcl.2017.05.005
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
17 beta-Hydroxysteroid dehydrogenase type 2 (17 beta-HSD2) converts the potent estrogen estradiol into the weakly active keto form estrone. Because of its expression in bone, inhibition of 17 beta-HSD2 provides an attractive strategy for the treatment of osteoporosis, a condition that is often caused by a decrease of the active sex steroids. Currently, there are no drugs on the market targeting 17 beta-HSD2, but in multiple studies, synthesis and biological evaluation of promising 17 beta-HSD2 inhibitors have been reported. Our previous work led to the identification of phenylbenzenesulfonamides and -sulfonates as new 17 beta HSD2 inhibitors by ligand-based pharmacophore modeling and virtual screening. In this study, new molecules representing this scaffold were synthesized and tested in vitro for their 17 beta-HSD2 activity to derive more profound structure-activity relationship rules. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2982 / 2985
页数:4
相关论文
共 25 条
[1]  
Bagi C. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P267
[2]   Estrogen and bone health in men and women [J].
Cauley, Jane A. .
STEROIDS, 2015, 99 :11-15
[3]   Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765
[4]   17β-hydroxysteroid dehydrogenases in human bone cells [J].
Dong, Y ;
Qiu, QQ ;
Debear, J ;
Lathrop, WF ;
Bertolini, DR ;
Tamburini, PP .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (10) :1539-1546
[5]   Selective estrogen receptor modulators in clinical practice: a safety overview [J].
Ellis, Amanda J. ;
Hendrick, Vicky M. ;
Williams, Robert ;
Komm, Barry S. .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) :921-934
[6]  
Elo JP, 1996, INT J CANCER, V66, P37, DOI 10.1002/(SICI)1097-0215(19960328)66:1<37::AID-IJC7>3.0.CO
[7]  
2-#
[8]   The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension [J].
Ferrari, Paolo .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2010, 1802 (12) :1178-1187
[9]   Comparative QSAR evidence for a free-radical mechanism of phenol-induced toxicity [J].
Hansch, C ;
McKarns, SC ;
Smith, CJ ;
Doolittle, DJ .
CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 127 (01) :61-72
[10]   European guidance for the diagnosis and management of osteoporosis in postmenopausal women [J].
Kanis, J. A. ;
McCloskey, E. V. ;
Johansson, H. ;
Cooper, C. ;
Rizzoli, R. ;
Reginster, J. -Y. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :23-57